For investors
Menu
For investors

Terapet announces international collaboration for Heavy Ion Therapy QA

KIAT/Innosuisses MoU signing ceremony

Terapet SA are proud to announce an international collaboration to develop a world-first device for patient-specific QA in heavy ion therapy (HIT). Terapet will be joined in the collaboration by Korean partners Yonsei Cancer Center and Oncosoft Inc, who together bring vital medical expertise and software innovations to be united with Terapet’s novel nuclear imaging […]

Christina, our CEO, invited as panel speaker at SEF – Swiss Economic Forum on funding and financing for startups in Switzerland

The SEF.Founder Conference at the Swiss Economic Forum is the highlight of the year for start-ups, scale-ups and SMEs. We offer top-class speakers and specific formats according to the needs of our SEF.Founder Community. In addition to the carefully compiled programme, it is the unique networking opportunity with partners and like-minded people that is particularly […]

We are happy to announce that Terapet SA has been awarded with the Innosuisse certificate

We are happy to announce that Terapet SA has been awarded with the Innosuisse certificate, which indicates the readiness for sustainable growth. The certificate is awarded to companies which have successfully mastered the start-up phase and are ready for long-term growth.Thanks to the Swiss Innovation Agency for all the support since the very start of […]

Terapet’s New Investment Round of CHF 2,3 M

Today, we are pleased to announce the new investment of CHF 2,3 million as the first closing of the Pre-Series A investment round. This funding supports the commercialization of Terapet’s first product, Qualγscan and the development of new nuclear imaging products. We would like to take this opportunity to thank all our investors, supporters and […]

New partnership – Terapet SA and The Politecnico di Milano

Geneva, June 1st, 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment, announced today the start of a new Research and Development partnership with The Politecnico di Milano – Dipartimento di Elettronica, Informazione e Bioingegneria. The R&D collaboration will be […]

Terapet SA is proud to announce: Terapet together with their world class R&D partners (CERN, Karolinska Institute and Skandion Clinic) are awarded a total of CHF 1’530’000 non-dilutive funds

Geneva, January 1 st , 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment, announced today the combined successful awards of a total of about CHF 1’530’000 non-dilutive funds. The combined funding supports the development of Terapet’s first full-scale prototype […]